Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II/III clinical trial of NTX-1024 for the treatment of patients with the vernal keratoconjunctivitis (VKC).

Next Previous
Trial Profile

Phase II/III clinical trial of NTX-1024 for the treatment of patients with the vernal keratoconjunctivitis (VKC).

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 04 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NTX 1024 (Primary)
  • Indications Keratoconjunctivitis
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 04 Mar 2026 New trial record
  • 19 Feb 2026 According to NexEos Bio Vision Health media release, this study is expected to began by the second half of this year.
  • 19 Feb 2026 According to NexEos Bio Vision Health media release, U.S. Food and Drug Administration (FDA) has cleared NexEos Investigational New Drug (IND) Application to proceed to a Phase II/III clinical trial of NTX-1024 for the treatment of patients with the rare disease, vernal keratoconjunctivitis (VKC).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top